The newly approved NephroScan may have promise in facilitating the diagnosis and assessment of renal disorders.
The Food and Drug Administration (FDA) has reportedly approved NephroScan, a radiodiagnostic imaging drug radiologists may utilize to help detect and assess renal parenchymal disorders.
Theragnostics says the imaging agent, which assists with preparation of the technetium Tc-99m succimer injection, may be utilized in adult and pediatric patients, including term neonates. GE Healthcare will be distributing NephroScan in the United States, according to Theragnostics.
Ted Treves, MD, said the FDA approval is welcome news for assessing patients with kidney disorders.
“The value of Tc-99m DMSA (dimercaptosuccinic acid) is well established in the assessment of disorders affecting the kidneys in children and adults,” noted Dr. Treves, a professor of radiology at Harvard Medical School and former chief of the Division of Nuclear Medicine at Boston Children’s Hospital. “The approval (of NephroScan) in the U.S. means that Tc-99m DMSA imaging will be brought back as a useful tool for the evaluation of adult and pediatric patients affected by renal diseases.”
Theragnostics noted that the biodistribution of Tc-99m DMSA, which principally binds to the cortical regions of the kidneys, “makes it a logical imaging agent for renal scintigraphy.”
In cases of acute renal infection, Theragnostics said TC-99m DMSA imaging has been utilized to identify patients at risk for sequelae including hypertension, parenchymal scarring, and chronic renal failure. Radiologists may also use Tc-99m DMSA imaging to ascertain split renal function, kidney shape and position, according to Theragnostics.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
AI Radiology ROI Calculator Study Projects 451 Percent ROI Over Five Years
March 18th 2024Incorporating an artificial intelligence (AI) platform into the radiology workflow at a stroke management-accredited hospital may lead to projected savings of 78 days in triage time and 41 days in reporting time for radiologists over a five-year period, according to new research.